This website will close on 30 April 2024. After this date, your content will not be accessible. Please contact for more information.

Under evaluation with potential for adoption
Share innovation

Preventing and reversing Type 2 Diabetes through precision fibre mixes

By Katherine Stennett, myota Added 29th Mar, 2022 Updated 6th May, 2022

myota develops precision fibre mixes to prevent and reverse incidences of chronic disease. Specifically, we are looking to tackle the ~4.5m cases of Type 2 diabetes in the UK, and help the 13.6m individuals at risk of Type 2 diabetes manage and reverse their symptoms. 

Our 'metabolic regulator' mix has been formulated to do this, firstly, by including viscous fibres have been shown to acutely lower postprandial glycaemic responses through the regulation of gastric emptying and nutrient absorption. Secondly, through the ability of fibre to trigger short-chain-fatty-acid production which subsequently influences glucose metabolism and insulin sensitivity.


It is well documented that microbial dysbiosis (imbalance) and inflammation originating in the gut is associated with a vast range of chronic diseases, from diabetes to depression.

Our founding team has spent that last decade studying the composition and fermentation capabilities of the gut microbiota (at Cambridge, MIT, and the University of Genera), and leveraged this research to create myota's precision dietary fibre mixes. Each mix is optimised to produce specific Short-Chain Fatty Acids (SCFAs), a by-product of the microbial fermentation process, which restores colonocyte health and reduces inflammation that underpins many chronic diseases.

A growing interest in microbiota-based interventions within the medical and research community has coincided with a patient-driven preference for alternative or adjunct therapies to manage these conditions, as opposed to pharmacological approaches. In the UK, 1 in 3 people have a least one risk factor for prediabetes – highlighting this as a key priority for the NHS. Our innovation therefore represents a promising and cost-effective therapeutic avenue, with conservative estimate of a £2m in-year saving for each ICS, and ~50m on a 5 year basis.

Our products are already in production and being sold to the general public, while we have our own clinical trial programme & research running concurrently, involves studies into diabetes, inflammation, and depression. Our team comprises some of the world's leading authorities on fibre fermentation and the gut microbiome, which we can leverage to support the implementation process, and adoption within the NHS.  

Useful resources

Related Innovations